Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

A subcutaneous version of the newly approved Alzheimer's drug lecanemab (Leqembi) may be on the horizon. Weekly subcutaneous lecanemab 100 mg/mL injection appeared to be as effective at amyloid plaque ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

Argenx has filed for FDA approval of subcutaneous efgartigimod, keeping it on track to start selling the sibling of its existing intravenous generalized myasthenia gravis (gMG) treatment Vyvgart. In ...

Eisai’s full-throttle development of a subcutaneous sibling to recently approved Alzheimer’s disease drug Leqembi could bear fruit in the coming quarters, with the Biogen-partnered drugmaker aiming to ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...

Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the ...

Subcutaneous fat is stored just beneath the skin and can be pinched with your fingers. Visceral fat lies deep within the abdominal walls and surrounds the organs. Visceral fat tends to cause bad ...